ALLMedicine™ Brain Cancer Center

Feb 3rd, 2023 - Despite the availability of multimodality approaches for localized gastric cancer, the survival rates remain dismal for resectable disease. There is a large unmet need to identify new therapeutic options, to be used in combination with chemotherap...

Feb 2nd, 2023 - Malignant brain tumors rank among the most challenging type of malignancies to manage. The current treatment protocol commonly entails surgery followed by radiotherapy and/or chemotherapy, however, the median patient survival rate is poor. Recent ...

Feb 1st, 2023 - It is estimated that between 50 and 80% of cancer patients in the United States (US) supplement their conventional medical treatment regimen with some form of complementary or alternative medicine (CAM) therapy or practice. A smaller percentage of...

Feb 1st, 2023 - The PI3K/AKT and p53 pathways are key regulators of cancer cell survival and death, respectively. Contrary to their generally accepted roles, several lines of evidence, including ours in medulloblastoma, the most common childhood brain cancer, hig...

Jan 31st, 2023 - Research identifying the needs of relatives of patients with an acquired brain injury or malignant brain tumours is emerging, and the importance of relative involvement is widely acknowledged. However, the intention of involvement does not seem to...

Nov 10th, 2020 - To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology of China (SNO-Chi...

Feb 3rd, 2023 - Despite the availability of multimodality approaches for localized gastric cancer, the survival rates remain dismal for resectable disease. There is a large unmet need to identify new therapeutic options, to be used in combination with chemotherap...

Feb 1st, 2023 - It is estimated that between 50 and 80% of cancer patients in the United States (US) supplement their conventional medical treatment regimen with some form of complementary or alternative medicine (CAM) therapy or practice. A smaller percentage of...

Jan 26th, 2023 - To prepare the brain cancer specific T cells (GD2-C7R T cells), research staff will take some blood from the patient. We will grow the GD2.C7R T cells by infecting the T cells with a retroviral vector (a special virus that can carry a new gene int...

Jan 20th, 2023 - Cognitive impairments experienced by cancer survivors, from time of diagnosis through the health trajectory, are distressing, persistent, and negatively impact everyday function and quality of life. While reports of cancer- and treatment-related c...

Jan 18th, 2023 - This first time-in patients (FTIP), open-label, multicentre study of AZD1390 will be conducted in the United States and in the United Kingdom, and it consists of three treatment arms: Arm A, B, C. This Phase 1 study will assess safety and tolerabi...

Dec 9th, 2022 - There has been an escalating risk of brain cancer associated with increasing radiation dose to the brain from CT examinations, a cohort study of more than 650,000 children and young adults indicated. Researchers observed a significant dose-respons...

Dec 8th, 2022 - Children and young adults who are exposed to a single CT scan of the head or neck before age 22 years are at significantly increased risk of developing a brain tumor, particularly glioma, after at least 5 years, according to results of the large E...

Dec 6th, 2022 - An investigational vaccine has significantly extended survival in patients with newly diagnosed as well as recurrent glioblastoma, according to new findings from a phase 3 trial (NCT00045968).   "Immunotherapy is a very promising approach for trea...

Nov 28th, 2022 - "Have you considered tissue donation?" These "five simple words" could have profound impact for pediatric brain cancer research — and for children with brain cancer and their families, according to pediatric neuro-oncologist Vijay Ramaswamy, MD, P...

Nov 1st, 2022 - Fam-trastuzumab deruxtecan-nxki (Enhertu) induced meaningful antitumor activity in patients with HER2-positive, HER2-low, or HER2-negative metastatic breast cancer who presented with brain metastases at baseline, according to data from the phase 2...